First treatment for primary progressive MS launched

Ocrevus (ocrelizumab) is the first disease-modifying agent to be licensed for the treatment of both relapsing and primary progressive forms of multiple sclerosis (MS).

by Lisa Lytle
 While MS has traditionally been considered to be predominantly a T-cell mediated disease, findings from the OPERA studies suggest that B cells play a role in its pathogenesis. | Medical Body Scans/SCIENCE PHOTO LIBRARY
While MS has traditionally been considered to be predominantly a T-cell mediated disease, findings from the OPERA studies suggest that B cells play a role in its pathogenesis. | Medical Body Scans/SCIENCE PHOTO LIBRARY

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package